Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
Patients undergoing major abdominal surgery are at highest risk for developing postoperative
ileus (POI), occurring in nearly all cases. Signs and symptoms of POI may include abdominal
distention, bloating, persistent abdominal pain; nausea and/or vomiting; delayed passage or
inability to pass flatus or stool; and inability to tolerate a solid diet. This study will
test the ability of alvimopan 6 mg or 12 mg given 2 hours before the scheduled start of
surgery to hasten the recovery of GI function in patients undergoing major abdominal surgery
(bowel resection or abdominal hysterectomy).